[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Merus N.V. Common Shares (MRUS)

Genmab to acquire Merus for $X billion, sending shares soaring. Positive clinical trial data and the acquisition have driven the stock to a 1-year high.

About Merus N.V. Common Shares

Merus N.V. Common Shares (MRUS) is a biopharmaceutical company developing cancer therapeutics.
Merus N.V. Common Shares uses the ticker $MRUS for trading. Listed in the Stocks and category within the Healthcare sectors.

Price: $XXXXX #

Price 24-Hour Time-Series Raw Data
The XXXXX% price surge in MRUS is driven by positive clinical trial results, analyst upgrades, and high social media engagement, with the stock price currently at $84.80, hitting a 1-year high, and the positive news indicates a likely continuation of the upward trend.

24-Hour	7-Day	30-Day
XXXX%	XXXX%	XXXXX%

1-Year High: $XXXXX on 2025-10-13
1-Year Low: $XXXXX on 2025-04-08

AltRank: XXX #

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Merus N.V. Common Shares (MRUS) is currently AltRank #478 based on combined combined social and market metrics Daily Average: XXX
1 Week: XXX +554
1 Month: XXX -XXX
6 Months: XXX +25
1 Year: XXX -XXX
1-Year High: XXXXX on 2025-08-12
1-Year Low: XX on 2025-05-25

Galaxy Score: XXXXX #

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
1 Week: XX -X
1 Month: XX +14
6 Months: XX +11
1 Year: XX +24
1-Year High: XX on 2025-07-10
1-Year Low: XX on 2025-09-19

Engagements: XXXXX #

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
1 Week: XXXXXX -XX%
1 Month: XXXXXXXXX +167%
6 Months: XXXXXXXXX +211%
1 Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-09-29
1-Year Low: XXX on 2025-04-18

Social Network	X
Engagements	XXXXX

Mentions: XX #

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
1 Month: XXX +106%
6 Months: XXXXX +331%
1 Year: XXXXX +545%
1-Year High: XXXXX on 2025-07-10
1-Year Low: X on 2024-10-18

Social Network	X
Mentions	XXX

Creators: XX #

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Merus N.V. Common Shares (MRUS) in the last XX hours which is down XX% from XX in the previous XX hours Daily Average: XX
1 Month: XXX +205%
6 Months: XXXXX +728%
1 Year: XXXXX +737%
1-Year High: XXX on 2025-09-30
1-Year Low: X on 2024-10-18

The most influential creators that mention Merus N.V. Common Shares in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@Fredbenz0	X	XXXXX	X	XXX
@eninvs_com	X	XXXXX	X	XXX
@bioinvestor24	X	XXXXX	X	XXX
@TheOptionsBull2	X	XXX	X	XXX
@OzmosiHealth	X	XXXXX	X	XXX
@BiopharmIQ	X	XXXXXX	X	XXX
@Biobeats99	X	XXX	X	XXX
@linhnguyen64143	X	XX	X	XX
@MichelleF_Davis	X	XXXXX	X	XX
@PersimmonTI	XX	XXXXXX	X	XX

Sentiment: XX% #

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% -XX%
1 Month: XX% +3%
6 Months: XX% -XX%
1 Year: XX% -XX%
1-Year High: XXX% on 2024-10-16
1-Year Low: X% on 2024-11-17

Most Supportive Themes

Positive Clinical Trial Data: (60%) Positive clinical trial results of Merus's drug, petosemtamab, particularly its high response and survival rates in head and neck cancer patients.
Analyst Price Target Increases: (20%) Several social media posts highlight analysts raising price targets for MRUS based on the promising clinical trial data.
Acquisition by Genmab: (15%) Genmab is acquiring Merus for $XX per share in cash, a deal valued at $X billion.

Most Critical Themes

Trial Data Comparison Concerns: (1%) Some users are expressing concerns over comparing trial results with different patient populations and treatment contexts.

Network engagement breakdown:

Network	Positive	%	Neutral	%	Negative	%
X	XXX	XX%	XXXXX	XX%	XXX	X%

Total	XXX	XX%	XXXXX	XX%	XXX	X%

Social Dominance: XXXXXXX% #

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
1 Week: XXXXXX% -XXXXX%
1 Month: XXXXX% +0.011%
6 Months: XXXXX% +0.0057%
1 Year: XXXXX% +0.0093%
1-Year High: XXXX% on 2025-05-25
1-Year Low: XXXXXX% on 2025-09-22

Market Dominance: XXXXXXX% #

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-03-31
1-Year Low: XXXXXXX% on 2025-02-14

Market Cap: $XXXXXXXXXXXXX #

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
1 Week: $XXXXXXXXXXXXX +$0.40%
1 Month: $XXXXXXXXXXXXX +$37%
6 Months: $XXXXXXXXXXXXX +$142%
1 Year: $XXXXXXXXXXXXX +$102%
1-Year High: $XXXXXXXXXXXXX on 2025-10-13
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08

Top assets mentioned In the posts about Merus N.V. Common Shares in the last XX hours

Credo Technology Group Holding Ltd Ordinary Shares (CRDO) Palantir (PLTR) Bitcoin Incognito (XBI) Akropolis (AKRO) BioMarin Pharmaceutical, Inc. (BMRN) Strategy (MSTR) AstraZeneca PLC (AZN) Avidity Biosciences, Inc. Common Stock (RNA) Vertex Protocol (VRTX)

Top topics mentioned In the posts about Merus N.V. Common Shares in the last XX hours

$gmab, $gmabco, stocks technology, stocks healthcare, $8b, acquisition, $crdo, stocks financial services, stocks bitcoin treasuries, $pltr, $xbi, $akro, investment, $psnl, $bmrn, $mstr, $etnb, $azn, $abvx, $rna, $nktr, $bntx, breakthrough, stocks, $97share, vertex protocol, $rytm, $pfe, stocks bitcoin miners, $mrk, $bmy, $wolf, $cart, $trml, $apge, targets, $argx, $asnd, stocks crypto treasuries, advanced micro devices, $ibrx, regeneron pharmaceuticals inc, stocks consumer cyclical, $idya, $mtsr, $prgo, $cort, dawn protocol, coins defi, $insm, $oklo, coins layer 1, $ths, $bgfv, electronic arts inc, stocks communication services, $ea, $8bn, $nuvl, $etor, $fro, $tmc, $arct, $sobi, $9700shr, $80b, $tlry, $pcvx, $ptct, akro akero therapeutics inc, tesla, bank of america, $frmi, $lgo, $mdgl, $mlys, $meso, $mltx, united states, $ymab, coins nft, $celg, $juno, occidental petroleum, $amat, stocks energy, $rog, $24b, goldman sachs, $gs, stocks consumer defensive, $bcas, all the, money, $qure, $bcax, $dwtx, launches, $1112b, $9b